Daniel Araujo

Dr. Daniel Araujo

Medical Oncologist at Hospital de Base, Sao Jose do Rio Preto - SP
orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2021 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PDF file
SKShawn P. Kubli
Shawn P. Kubli
TBThorsten Berger
Thorsten Berger
DADaniel V. Araujo
Daniel V. Araujo
LSLillian L. Siu
Lillian L. Siu
TMTak W. Mak
Tak W. Mak

27 February 2015 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
EAEmne Ali Abdallah
Emne Ali Abdallah
MFMarcello Ferretti Fanelli
Marcello Ferretti Fanelli
MBMarcilei Eliza Cavicchioli Buim
Marcilei Eliza Cavicchioli Buim
MNMarcelo Calil Machado Netto
Marcelo Calil Machado Netto
JJJosé Luiz Gasparini Junior
José Luiz Gasparini Junior
LCLudmilla Chinen
Ludmilla Chinen
Thymidylate synthase (TYMS) is an important enzyme for 5-fluorouracil (5-FU) metabolism in metastatic colorectal cancer (mCRC) patients. The search for this enzyme in circulating tumor cells (CTCs) can be a powerful tool to follow-up cancer patients. mCRC patients were enrolled before the beginning of 5-FU-based chemotherapy. The blood was filtered on Isolation by Size of Epithelial Tumor Cells (ISET), and the analysis of TYMS expression in CTCs was made by immunocytochemistry. Additionally, we verified TYMS staining in primary tumors and metastases from the same patients. There were included 54 mCRC patients and 47 of them received 5-FU-based chemotherapy. The median CTCs number was 2 per mL. We were not able to analyze immunocytochemistry in 13 samples (9 patients with absence of CTCs and 4 samples due to technical reasons). Therefore, TYMS expression on CTCs was analyzed in 34 samples and was found positive in 9 (26.5%). Six of these patients had tumor progression after treatment with 5-FU. We found an association between CTC TYMS staining and disease progression (DP), although without statistical significance (P = 0.07). TYMS staining in primary tumors and metastases tissues did not have any correlation with disease progression (P = 0.67 and P = 0.42 respectively). Patients who had CTC count above the median (2 CTCs/mL) showed more TYMS expression (P = 0.02) correlating with worse prognosis. Our results searching for TYMS staining in CTCs, primary tumors and metastases suggest that the analysis of TYMS can be useful tool as a 5-FU resistance predictor biomarker if analyzed in CTCs from mCRC patients.

1 October 2021 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
MOMarc Oliva
Marc Oliva
DCDouglas Chepeha
Douglas Chepeha
DADaniel V Araujo
Daniel V Araujo
JDJ. Javier Diaz-Mejia
J. Javier Diaz-Mejia
POPeter Olson
Peter Olson
LSLillian L. Siu
Lillian L. Siu
Background Sitravatinib, a tyrosine kinase inhibitor that targets TYRO3, AXL, MERTK and the VEGF receptor family, is predicted to increase the M1 to M2-polarized tumor-associated macrophages ratio in the tumor microenvironment and have synergistic antitumor activity in combination with anti-programmed death-1/ligand-1 agents. SNOW is a window-of-opportunity study designed to evaluate the immune and molecular effects of preoperative sitravatinib and nivolumab in patients with oral cavity squamous cell carcinoma. Methods Patients with newly-diagnosed untreated T2-4a, N0-2 or T1 >1 cm-N2 oral cavity carcinomas were eligible. All patients received sitravatinib 120 mg daily from day 1 up to 48 hours pre-surgery and one dose of nivolumab 240 mg on day 15. Surgery was planned between day 23 and 30. Standard of care adjuvant radiotherapy was given based on clinical stage. Tumor photographs, fresh tumor biopsies and blood samples were collected at baseline, at day 15 after sitravatinib alone, and at surgery after sitravatinib–nivolumab combination. Tumor flow cytometry, multiplex immunofluorescence staining and single-cell RNA sequencing (scRNAseq) were performed on tumor biopsies to study changes in immune-cell populations. Tumor whole-exome sequencing and circulating tumor DNA and cell-free DNA were evaluated at each time point. Results Ten patients were included. Grade 3 toxicity occurred in one patient (hypertension); one patient required sitravatinib dose reduction, and one patient required discontinuation and surgery delay due to G2 thrombocytopenia. Nine patients had clinical-to-pathological downstaging, with one complete response. Independent pathological treatment response (PTR) assessment confirmed a complete PTR and two major PTRs. With a median follow-up of 21 months, all patients are alive with no recurrence. Circulating tumor DNA and cell-free DNA dynamics correlated with clinical and pathological response and distinguished two patient groups with different tumor biological behavior after sitravatinib alone (1A) versus sitravatinib–nivolumab (1B). Tumor immunophenotyping and scRNAseq analyses revealed differential changes in the expression of immune cell populations and sitravatinib-targeted and hypoxia-related genes in group 1A vs 1B patients. Conclusions The SNOW study shows sitravatinib plus nivolumab is safe and leads to deep clinical and pathological responses in oral cavity carcinomas. Multi-omic biomarker analyses dissect the differential molecular effects of sitravatinib versus the sitravatinib–nivolumab and revealed patients with distinct tumor biology behavior. Trial registration number NCT03575598.

7 March 2016 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
EAEmne Ali Abdallah
Emne Ali Abdallah
MFMarcello Ferretti Fanelli
Marcello Ferretti Fanelli
VSVirgilio Souza e Silva
Virgilio Souza e Silva
MNMarcelo Calil Machado Netto
Marcelo Calil Machado Netto
JJJosé Luiz Gasparini Junior
José Luiz Gasparini Junior
LCLudmilla Chinen
Ludmilla Chinen

1 November 2021 in European Journal of Cancer
Verified
Journal Article
Closed access
DADaniel V. Araujo
Daniel V. Araujo
MOMarc Oliva
Marc Oliva
KLKecheng Li
Kecheng Li
RFRouhi Fazelzad
Rouhi Fazelzad
ZLZhihui Amy Liu
Zhihui Amy Liu
LSLillian L. Siu
Lillian L. Siu

16 November 2024 in ESMO Open
Verified
Journal Article
Open access
SGS. Genta
S. Genta
DAD.V. Araujo
D.V. Araujo
KHK. Hueniken
K. Hueniken
CPC. Pipinikas
C. Pipinikas
RVR. Ventura
R. Ventura
PCPrincess Margaret Cancer Centre
Princess Margaret Cancer Centre
Locally advanced melanoma has a variable prognosis. Currently, there are no reliable criteria to stratify the risk of disease relapse and identify those patients who will benefit the most from adjuvant therapies. Circulating tumor DNA (ctDNA) is an emerging biomarker measuring the presence of tumor-derived DNA in blood. We used a bespoke, tumor-informed assay (RaDaR®, NeoGenomics, Inc.) to detect ctDNA in 276 prospectively collected plasma samples from 66 melanoma patients receiving definitive treatment. Collection time points included landmark (after completion of local treatment) and every 3-6 months for up to 2 years. ctDNA was detected in at least one plasma sample in 19 patients (29%), including 6/65 (9%) at landmark (post-surgical sample). Positive ctDNA at landmark was associated with shorter overall survival (OS; median OS 22.7 months versus not reached, log-rank P value = 0.01) and a trend towards a shorter relapse-free survival (RFS; median RFS 15.7 months versus not reached, log-rank P value = 0.07). In 10 patients, ctDNA detection preceded disease relapse by a median of 128 days (range 8-406 days). Our data indicate that ctDNA detection after surgery can identify patients with worse prognosis, and serial ctDNA measurements may enable earlier identification of disease recurrence.